Abdellah Ahmed Mostafa Ahmed, Batool Amna, Mohammad Rababah Aws Khaled, Minhas Madeeha, Jehangir Abdul Mannan, Sana Maryum, Haseeb Muhammad, Mzahri Ehsan Ul Haq
General Surgery, October 6th University Hospital, 6th of October City, EGY.
Surgery, Fatima Memorial Hospital, Lahore, PAK.
Cureus. 2025 Apr 8;17(4):e81881. doi: 10.7759/cureus.81881. eCollection 2025 Apr.
Head and neck squamous cell carcinoma (HNSCC) is a widespread malignancy and has high morbidity and mortality rates. Identifying reliable biomarkers can help in improvement of diagnosis, prognosis, and treatment response. This systematic review aimed to evaluate the diagnostic potential of various novel biomarkers against HNSCC. A comprehensive search was taken place using PubMed, Scopus, Web of Science, and Google scholar that covered range of studies published from 2019 to 2025. The search focused on biomarkers that related to HNSCC and its correlation with clinical outcomes such as survival rates and treatment response. Studies were selected on the basis of predefined eligibility criteria and included observational and experimental study designs. Data extraction was performed by two independent reviewers. Study quality was assessed using the Newcastle-Ottawa Scale and the Cochrane Risk of Bias Tool for respective study designs. The quality of the evidence was evaluated using the GRADE approach. A total of 12 studies were included in this review after full screening process. The studies evaluated several biomarkers that indicated towards significant correlations between certain biomarkers and HNSCC prognosis. Elevated levels of expression of specific biomarkers were associated with poor survival outcomes, while others showed promise in the prediction of recurrence and treatment efficacy. The review highlighted the effectiveness of novel biomarkers for improving the HNSCC management. However, further validation of these findings and establish biomarkers for clinical use.
头颈部鳞状细胞癌(HNSCC)是一种广泛存在的恶性肿瘤,发病率和死亡率都很高。识别可靠的生物标志物有助于改善诊断、预后和治疗反应。本系统评价旨在评估各种新型生物标志物对头颈部鳞状细胞癌的诊断潜力。使用PubMed、Scopus、Web of Science和谷歌学术进行了全面检索,涵盖了2019年至2025年发表的一系列研究。检索重点是与头颈部鳞状细胞癌相关的生物标志物及其与生存率和治疗反应等临床结果的相关性。根据预先确定的纳入标准选择研究,包括观察性和实验性研究设计。由两名独立的评审员进行数据提取。使用纽卡斯尔-渥太华量表和针对各自研究设计的Cochrane偏倚风险工具评估研究质量。使用GRADE方法评估证据质量。经过全面筛选过程,本综述共纳入12项研究。这些研究评估了几种生物标志物,表明某些生物标志物与头颈部鳞状细胞癌预后之间存在显著相关性。特定生物标志物表达水平升高与不良生存结果相关,而其他生物标志物在预测复发和治疗疗效方面显示出前景。该综述强调了新型生物标志物在改善头颈部鳞状细胞癌管理方面的有效性。然而,需要进一步验证这些发现并建立用于临床的生物标志物。